.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Moodys
Merck
US Department of Justice
Citi
US Army
McKesson
Novartis
Colorcon
Baxter

Generated: July 27, 2017

DrugPatentWatch Database Preview

Pf Prism Cv Company Profile

« Back to Dashboard

What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?

PF PRISM CV has fourteen approved drugs.

There are thirty-nine US patents protecting PF PRISM CV drugs and there have been two Paragraph IV challenges on PF PRISM CV drugs in the past three years.

There are eight hundred and twenty-one patent family members on PF PRISM CV drugs in seventy-six countries.

Summary for Applicant: Pf Prism Cv

Patents:39
Tradenames:10
Ingredients:10
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-004Dec 30, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
XALKORI
crizotinib
CAPSULE;ORAL202570-002Aug 26, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
XELJANZ
tofacitinib citrate
TABLET;ORAL203214-001Nov 6, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-007Dec 30, 2004RXYesNo► Subscribe► Subscribe ► Subscribe
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-008Dec 30, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pf Prism Cv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-003Dec 30, 2004► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-002Aug 22, 2002► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-002Aug 22, 2002► Subscribe► Subscribe
Pf Prism Cv
RAPAMUNE
sirolimus
TABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PF PRISM CV drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinib
Tablets5 mg
XELJANZ 
11/7/2016
bosutinib
Tablets100mg and 500mg
BOSULIF
9/6/2016
temsirolimus
Injection25 mg/mL, 1.8 mL vial
TORISEL
5/25/2011
voriconazole
Oral Suspension40 mg/mL
VFEND
10/8/2010
sirolimus
Tablets0.5 mg
RAPAMUNE
8/25/2010
pregabalin
Oral Solution20 mg/mL
LYRICA
5/19/2010
sirolimus
Tablets1 mg and 2 mg
RAPAMUNE
12/17/2009
tigecycline
For Injection50 mg per vial
TYGACIL
6/15/2009
pregabalin
Capsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg
LYRICA
12/30/2008
voriconazole
For Injection200 mg/vial
VFEND
9/12/2008
voriconazole
Tablets50 mg and 200 mg
VFEND
4/14/2008

Non-Orange Book Patents for Pf Prism Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,710,304 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,291,526 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
7,141,587Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use► Subscribe
6,627,754 Pyrrolo[2,3-d]pyrimidine compounds► Subscribe
6,255,345 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pf Prism Cv Drugs

Country Document Number Estimated Expiration
Russian Federation2384331► Subscribe
Turkey200400105► Subscribe
EcuadorSP077276► Subscribe
Russian Federation2140901► Subscribe
Japan4619346► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.



Supplementary Protection Certificates for Pf Prism Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
8Finland► Subscribe
00348Netherlands► SubscribePRODUCT NAME: TEMSIROLIMUS, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
2004017Lithuania► SubscribePRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RûGðTIS)
112Luxembourg► Subscribe91112, EXPIRES: 20180518
0244Netherlands► SubscribePRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Federal Trade Commission
Mallinckrodt
Teva
Moodys
Merck
Dow
Chubb
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot